AXSM · Axsome Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on AXSM. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About AXSM · Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Live Quote
HOLD (score +3) · 12-1 mom 124.1% · RSI 55.7 · above_both · -5.2% from high
Targets blend Wall Street consensus (21 analysts: low $200.00 / mean $276.47 / high $380.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The dossier lacks insider conviction, shows a recent earnings miss, trades at an all-time high with no margin of safety, and features a binary catalyst that has already passed with an unknown outcome. No viable structure emerges from the data.
The dossier lacks insider conviction, shows a recent earnings miss, trades at an all-time high with no margin of safety, and features a binary catalyst that has already passed with an unknown outcome. No viable structure emerges from the data.
Investigation found 8 Form 4 filings in the last ~14 days but NO open-market P (purchase) transactions verified. The cluster consists entirely of RSU vest-converts and option-exercise-plus-immediate-sell patterns (all under pre-set 10b5-1 plans), not discretionary open-market stock purchases that would signal insider conviction. CEO Herriot Tabuteau exercised ~49,670 options at $4.95 strike on June 9 and sold at market ($241 avg) for ~$12M gross — a net gain transaction but coded as M/S (exercise-then-sale under a plan), not an open-market P buy. The company has genuine catalysts: AXS-05 PDUFA date of April 30, 2026 appears to have passed without public approval/rejection disclosure; Auvelity launch in Alzheimer's agitation is underway per June conference presentations; SUNOSI patent resolution through 2040 was just announced (June 3). However, at $246 the stock is at all-time highs with a forward P/E of ~42x on negative EBITDA, and RSI is elevated at 69. The bullish thesis rests on revenue momentum (+57% YoY) and pipeline optionality — not insider signals.